Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus

International Journal of Antimicrobial Agents

Volumn 35, Issue 2, 2010, Pages 146-151

  Warn, Peter A ^a   Sharp, Andrew ^a   Morrissey, Graham ^a   Denning, David W ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Aminocandin; Aspergillus fumigatus; Mouse; Neutropenic

Indexed keywords

AMINOCANDIN; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; CASPOFUNGIN; CYCLOPHOSPHAMIDE; HMR 3270; IP 960; ITRACONAZOLE; MICAFUNGIN; NXL 201; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EFFICACY; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; FUNGUS CULTURE; FUNGUS GROWTH; KIDNEY PARENCHYMA; LIVER; MALE; MORTALITY; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SURVIVAL RATE;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; ECHINOCANDINS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; ITRACONAZOLE; KIDNEY; LIPOPEPTIDES; LIVER; MALE; MICE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 72449133384     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.09.029     Document Type: Article

References (36)

1. Denning D.W. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 23 (1996) 608-615
2. Groll A.H., Shah P.M., Mentzel C., Schneider M., Just-Nuebling G., and Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 33 (1996) 23-32
3. McNeil M.M., Nash S.L., Hajjeh R.A., Phelan M.A., Conn L.A., Plikaytis B.D., et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 33 (2001) 641-647
4. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 (2002) 408-415
5. Pagano L., Caira M., Picardi M., Candoni A., Melillo L., Fianchi L., et al. Invasive aspergillosis in patients with acute leukemia: update on morbidity and mortality-SEIFEM-C Report. Clin Infect Dis 44 (2007) 1524-1525
6. Nivoix Y., Velten M., Letscher-Bru V., Moghaddam A., Natarajan-Amé S., Fohrer C., et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 47 (2008) 1176-1184
7. Denning D.W., Ribaud P., Milpied N., Caillot D., Herbrecht R., Thiel E., et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 34 (2002) 563-571
8. Langner S., Staber P.B., and Neumeister P. Posaconazole in the management of refractory invasive fungal infections. Ther Clin Risk Manag 4 (2008) 747-758
9. Tawara S., Ikeda F., Maki K., Morishita Y., Otomo K., Teratani N., et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 44 (2000) 57-62
10. Ikeda F., Wakai Y., Matsumoto S., Maki K., Watabe E., Tawara S., et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 44 (2000) 614-618
11. Abruzzo G.K., Flattery A.M., Gill C.J., Kong L., Smith J.G., Pikounis V.B., et al. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 41 (1997) 2333-2338
12. Moore C.B., and Denning D.W. In vitro activity of HMR3270 against Candida sp. Abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy (ICAAC), 16-19 December 2001, Chicago, IL (2001), ASM Press, Washington, DC [Abstract F-2147]
13. Andes D., Marchillo K., Lowther J., Bryskier A., Stamstad T., and Conklin R. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother 47 (2003) 1187-1192
14. Warn P.A., Sharp A., Morrissey G., and Denning D.W. Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis. J Antimicrob Chemother 56 (2005) 590-593
15. Warn P., Sharp A., Morrissey G., and Denning D.W. The in vivo activity of HMR3270 in temporarily neutropenic murine models of disseminated infection caused by Aspergillus fumigatus (2 strains). Abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy (ICAAC), 16-19 December 2001, Chicago, IL (2001), ASM Press, Washington, DC [Abstract J-1618]
16. Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect 2008;14:982-4 [Erratum in: Clin Microbiol Infect 2009;15:103].
17. Cuenca-Estrella M., Arendrup M.C., Chryssanthou E., Dannaoui E., Lass-Florl C., Sandven P., et al. Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect 13 (2007) 1018-1022
18. Warn P.A., Morrissey G., Morrissey J., and Denning D.W. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J Antimicrob Chemother 51 (2003) 913-919
19. Denning D.W., Radford S.A., Oakley K.L., Hall L., Johnson E.M., and Warnock D.W. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 40 (1997) 401-414
20. Denning D.W., Tucker R.M., Hanson L.H., and Stevens D.A. Treatment of invasive aspergillosis with itraconazole. Am J Med 86 (1989) 791-800
21. Johnson E.M., Oakley K.L., Radford S.A., Moore C.B., Warn P., Warnock D.W., et al. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother 45 (2000) 85-93
22. Howard S.J., Webster I., Moore C.B., Gardiner R.E., Park S., Perlin D.S., et al. Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents 28 (2006) 450-453
23. Snelders E., van der Lee H.A., Kuijpers J., Rijs A.J., Varga J., Samson R.A., et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 5 (2008) e219
24. Bartizal K., Gill C.J., Abruzzo G.K., Flattery A.M., Kong L., Scott P.M., et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 41 (1997) 2326-2332
25. Dannaoui E., Borel E., Persat F., Piens M.A., and Picot S. Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis. J Med Microbiol 49 (2000) 601-606
26. Oakley K.L., Morrissey G., and Denning D.W. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother 41 (1997) 1504-1507
27. Sugar A.M., and Liu X.P. Effect of grapefruit juice on serum voriconazole concentrations in the mouse. Med Mycol 38 (2000) 209-212
28. Bowman J.C., Hicks P.S., Kurtz M.B., Rosen H., Schmatz D.M., Liberator P.A., et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 46 (2002) 3001-3012
29. Bowman J.C., Abruzzo G.K., Anderson J.W., Flattery A.M., Gill C.J., Pikounis V.B., et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 45 (2001) 3474-3481
30. Verweij P.E., Oakley K.L., Morrissey J., Morrissey G., and Denning D.W. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother 42 (1998) 873-878
31. O'Sullivan C.E., Kasai M., Francesconi A., Petraitis V., Petraitiene R., Kelaher A.M., et al. Development and validation of a quantitative real-time PCR assay using fluorescence resonance energy transfer technology for detection of Aspergillus fumigatus in experimental invasive pulmonary aspergillosis. J Clin Microbiol 41 (2003) 5676-5682
32. Warn P.A., Sharp A., Guinea J., and Denning D.W. Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida. J Antimicrob Chemother 53 (2004) 743-749
33. Warn P.A., Sharp A., Parmar A., Majithiya J., Denning D.W., and Hope W.W. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob Agents Chemother 53 (2009) 3453-3461
34. Hohl T.M., Feldmesser M., Perlin D.S., and Pamer E.G. Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal β-glucan exposure. J Infect Dis 198 (2008) 176-185
35. Maertens J., Glasmacher A., Herbrecht R., Thiebaut A., Cordonnier C., Segal B.H., et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107 (2006) 2888-2897
36. Denning D.W., Marr K.A., Lau W.M., Facklam D.P., Ratanatharathorn V., Becker C., et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 53 (2006) 337-349